期刊文献+

体外冲击波治疗早中期膝关节骨性关节炎效果观察及其机制 被引量:19

下载PDF
导出
摘要 目的探讨体外冲击波(ESW)治疗早中期膝关节骨性关节炎(KOA)的临床疗效及其可能的机制。方法选择65例早中期KOA患者,与患者说明治疗方案后按患者意愿分为观察组33例和对照组32例。观察组采用ESW治疗(1次/周);对照组口服塞来昔布胶囊,200 mg/次,1次/d;两组疗程均为4周。两组分别于治疗前、治疗后即刻及治疗后2、6个月行疼痛视觉模拟评分(VAS)评价疼痛情况,采用WOMAC骨性关节炎指数评分(简称WOMAC评分)评价膝关节功能,采用ELISA法检测关节液IL-1β、IL-10和NO。结果与治疗前比较,观察组治疗后即刻、治疗后2个月、治疗后6个月VAS及WOMAC评分均降低,对照组治疗后即刻、治疗后2个月VAS及WOMAC评分均降低(P均<0.05)。观察组治疗后2、6个月VAS及WOMAC评分均低于对照组(P均<0.05)。与治疗前比较,观察组治疗后即刻、治疗后2个月、治疗后6个月关节液IL-1β和NO水平均降低,对照组治疗后即刻、治疗后2个月关节液IL-1β和NO水平均降低(P均<0.05)。观察组治疗后2、6个月关节液IL-1β和NO水平均低于对照组,治疗后即刻及治疗后2个月关节液IL-10水平均高于治疗前及对照组治疗后(P均<0.05)。结论ESW治疗早中期KOA疗效较好、作用时间长;降低关节液IL-1β、NO水平及升高IL-10水平可能是其作用机制。
出处 《山东医药》 CAS 北大核心 2016年第48期60-62,共3页 Shandong Medical Journal
基金 广西科学研究与技术开发计划项目(桂科攻1598012-10) 广西医疗卫生适宜技术研究与开发项目(S201313-05)
  • 相关文献

参考文献1

二级参考文献46

  • 1Nawrot R, Wolufi Cholewa M, Go.dzicka-J6zefiak A. Nucleases isolated from Chelidonium majus I,. milky sap can induce apoptosis in human cervical carcinoma HeLa cells but not in Chinese Hamster Ovary CHO cells. Folia Histochem Cytobiol. 2008; 46(1): 79-83.
  • 2Moro PA, Cassetti F, Giugliano G, Falce MT, Mazzanti G, Menniti-Ippolito F, Raschetti R, Santuceio C. Hepatitis from greater celandine (Chelidonium rnajus L.): review of literature and report of a new case. J Ethnopharmacol. 2009; 124(2): 328-332.
  • 3Gilca M, Gaman L, Panait E, Stoian I, Atanasiu V. Chelidonium majus -- an integrative review: traditional knowledge versus modem findings. Forsch Komplementmed. 2010; 17(5): 241-248.
  • 4Biswas SJ, Khuda-Bukhsh AR. Effect of a homeopathicdrug, Chelidonium, in amelioration of p-DAB induced hepatocarcinogenesis in mice. BMC Complement Altern Med. 2002: 2: 4.
  • 5Biswas SJ, Khuda-Bukhsh AR. Evaluation of protective potentials of a potentized homeopathic drug, Chelidonium rnajus, during azo dye induced hepatocarcinogenesis in mice. IndianJ ExpBiol. 2004; 42(7): 698-714.
  • 6Biswas SJ, Bhattacharjee N, Khuda-Bukhsh AR. Efficacy of a plant extract (Chelidonium rnajus L. ) in combating induced hepatocarcinogenesis in mice. Food Chem Toxicol. 2008; 46(5) : 1474-1487.
  • 7K6ry A, Horvfith J, Nfisz I, Verzfir-Petri G, Kulcsfir G, Dfin P. Antiviral alkaloid in Chelidonium majus L. ActaPharm Hung. 1987; 57(1-2): 19-25.
  • 8Lenfeld J, Kroutil M, Marsfilek E, Slavik J, Preininger V, Sim/mek V. Antiinflammatory activity o{ quaternary benzophenanthridine alkaloids from Chelidonium majus. Planta Med. 1981; 43(2): 161-165.
  • 9Colombo ML, Bosisio E. Pharmacological activities of Chelidonium majus L. ( Papaveraceae ). Pharmacol Res. 1996; 33(2): 127-134.
  • 10Staniszewski A, Slesak B, Kofodziej J, Harlozifiska- Szmyrka A, Nowicky JW. Lymphocyte subsets in patients with lung cancer treated with thiophosphoric acid alkaloid derivatives {rom Chelidonium majus L. ( Ukrain ). Drugs Exp Clin Res. 1992; 18(Suppl) : 63 67.

共引文献9

同被引文献156

引证文献19

二级引证文献83

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部